- Home
- YQ vs BCAB Comparison
YQ vs BCAB Comparison
Compare YQ & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- BCAB
- Stock Information
- Founded
- YQ 2012
- BCAB 2007
- Country
- YQ China
- BCAB United States
- Employees
- YQ N/A
- BCAB N/A
- Industry
- YQ Other Consumer Services
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- YQ Real Estate
- BCAB Health Care
- Exchange
- YQ Nasdaq
- BCAB Nasdaq
- Market Cap
- YQ 19.4M
- BCAB 21.6M
- IPO Year
- YQ 2020
- BCAB 2020
- Fundamental
- Price
- YQ $1.98
- BCAB $0.44
- Analyst Decision
- YQ
- BCAB Hold
- Analyst Count
- YQ 0
- BCAB 3
- Target Price
- YQ N/A
- BCAB $1.00
- AVG Volume (30 Days)
- YQ 18.6K
- BCAB 490.6K
- Earning Date
- YQ 08-27-2025
- BCAB 08-07-2025
- Dividend Yield
- YQ N/A
- BCAB N/A
- EPS Growth
- YQ N/A
- BCAB N/A
- EPS
- YQ N/A
- BCAB N/A
- Revenue
- YQ $25,546,613.00
- BCAB $11,000,000.00
- Revenue This Year
- YQ N/A
- BCAB N/A
- Revenue Next Year
- YQ N/A
- BCAB N/A
- P/E Ratio
- YQ N/A
- BCAB N/A
- Revenue Growth
- YQ N/A
- BCAB N/A
- 52 Week Low
- YQ $1.26
- BCAB $0.24
- 52 Week High
- YQ $3.19
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- YQ 48.60
- BCAB 60.38
- Support Level
- YQ $1.91
- BCAB $0.35
- Resistance Level
- YQ $2.06
- BCAB $0.38
- Average True Range (ATR)
- YQ 0.06
- BCAB 0.03
- MACD
- YQ 0.01
- BCAB 0.01
- Stochastic Oscillator
- YQ 73.08
- BCAB 100.00
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.